Oculis Holding AG
NASDAQ:OCS
Gross Margin
Oculis Holding AG
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CH |
O
|
Oculis Holding AG
NASDAQ:OCS
|
1B USD | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
618.2B USD |
83%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
417.4B USD |
68%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
197.8B CHF |
74%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
176.8B GBP |
82%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
188.6B CHF |
76%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
84%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
207.4B USD |
78%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.6B USD |
74%
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Oculis Holding AG's most recent financial statements, the company has Gross Margin of 0%.